HRP20171248T1 - Amino-supstituirani imidazopiridazini - Google Patents

Amino-supstituirani imidazopiridazini Download PDF

Info

Publication number
HRP20171248T1
HRP20171248T1 HRP20171248TT HRP20171248T HRP20171248T1 HR P20171248 T1 HRP20171248 T1 HR P20171248T1 HR P20171248T T HRP20171248T T HR P20171248TT HR P20171248 T HRP20171248 T HR P20171248T HR P20171248 T1 HRP20171248 T1 HR P20171248T1
Authority
HR
Croatia
Prior art keywords
imidazo
benzofuran
oxy
pyridazin
alkyl
Prior art date
Application number
HRP20171248TT
Other languages
English (en)
Croatian (hr)
Inventor
Knut Eis
Florian PÜHLER
Ludwig Zorn
Arne Scholz
Philip Lienau
Mark Jean Gnoth
Ulf Bömer
Judith GÜNTHER
Marion Hitchcock
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47831558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171248(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of HRP20171248T1 publication Critical patent/HRP20171248T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)
HRP20171248TT 2011-09-06 2012-09-05 Amino-supstituirani imidazopiridazini HRP20171248T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11180129 2011-09-06
EP11182440 2011-09-23
EP12179902 2012-08-09
PCT/EP2012/067264 WO2013034570A1 (en) 2011-09-06 2012-09-05 Amino-substituted imidazopyridazines
EP12761564.9A EP2758401B1 (en) 2011-09-06 2012-09-05 Amino-substituted imidazopyridazines

Publications (1)

Publication Number Publication Date
HRP20171248T1 true HRP20171248T1 (hr) 2017-10-20

Family

ID=47831558

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171248TT HRP20171248T1 (hr) 2011-09-06 2012-09-05 Amino-supstituirani imidazopiridazini

Country Status (36)

Country Link
US (1) US9499547B2 (OSRAM)
EP (1) EP2758401B1 (OSRAM)
JP (1) JP6174583B2 (OSRAM)
KR (1) KR20140059268A (OSRAM)
CN (1) CN103958515B (OSRAM)
AP (1) AP2014007496A0 (OSRAM)
AU (1) AU2012306422B2 (OSRAM)
BR (1) BR112014004687A2 (OSRAM)
CA (1) CA2847514A1 (OSRAM)
CL (1) CL2014000543A1 (OSRAM)
CO (1) CO6900146A2 (OSRAM)
CR (1) CR20140113A (OSRAM)
CY (1) CY1119433T1 (OSRAM)
DK (1) DK2758401T3 (OSRAM)
DO (1) DOP2014000051A (OSRAM)
EA (1) EA025688B1 (OSRAM)
EC (1) ECSP14013231A (OSRAM)
ES (1) ES2638319T3 (OSRAM)
GT (1) GT201400043A (OSRAM)
HR (1) HRP20171248T1 (OSRAM)
IL (1) IL231351A (OSRAM)
LT (1) LT2758401T (OSRAM)
MA (1) MA35422B1 (OSRAM)
ME (1) ME02951B (OSRAM)
MX (1) MX348064B (OSRAM)
MY (1) MY168413A (OSRAM)
PE (1) PE20141593A1 (OSRAM)
PH (1) PH12014500501A1 (OSRAM)
PL (1) PL2758401T3 (OSRAM)
PT (1) PT2758401T (OSRAM)
RS (1) RS56179B1 (OSRAM)
SG (1) SG11201400219PA (OSRAM)
SI (1) SI2758401T1 (OSRAM)
UA (1) UA117092C2 (OSRAM)
WO (1) WO2013034570A1 (OSRAM)
ZA (1) ZA201402498B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103717604B (zh) 2011-06-01 2016-06-01 拜耳知识产权有限责任公司 取代的氨基咪唑并哒嗪
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
US9320737B2 (en) * 2011-09-23 2016-04-26 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
CA2858685A1 (en) 2011-12-12 2013-06-20 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
ES2663609T3 (es) * 2012-03-29 2018-04-16 Bayer Intellectual Property Gmbh Imidazopiridazinas amino-sustituidas
EP2834245B1 (en) 2012-04-04 2017-12-13 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
EP2920176B1 (en) 2012-11-19 2017-09-13 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines as mknk1 kinase inhibitors
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CN105008363A (zh) * 2013-01-30 2015-10-28 拜耳医药股份公司 作为mknk-1激酶抑制剂的酰氨基咪唑并哒嗪
HK1212699A1 (zh) * 2013-02-20 2016-06-17 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CN105899512A (zh) 2014-01-09 2016-08-24 拜耳医药股份公司 可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
CN107108636A (zh) * 2014-12-23 2017-08-29 拜耳医药股份公司 6‑羟基苯并呋喃基‑和6‑烷氧基苯并呋喃基‑取代的咪唑并哒嗪
KR102891799B1 (ko) 2015-04-20 2025-11-26 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017117052A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2017157418A1 (en) 2016-03-15 2017-09-21 Bayer Pharma Aktiengesellschaft Combination of mknk1-inhibitors
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4408047A (en) 1980-03-28 1983-10-04 Merck & Co., Inc. Imidazodiazines
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
FR2619818B1 (fr) 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US20040254189A1 (en) 2001-08-23 2004-12-16 Hideaki Nagaya Jnk inhibitors
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
ATE456565T1 (de) 2006-06-22 2010-02-15 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
CN101594909A (zh) * 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
WO2009060197A1 (en) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
EP2235019A1 (en) 2007-12-21 2010-10-06 Wyeth LLC Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
CA2836203A1 (en) * 2011-05-17 2012-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
CN103717604B (zh) 2011-06-01 2016-06-01 拜耳知识产权有限责任公司 取代的氨基咪唑并哒嗪
HK1197063A1 (en) 2011-06-22 2015-01-02 拜耳知识产权有限责任公司 Heterocyclyl aminoimidazopyridazines
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
US9320737B2 (en) 2011-09-23 2016-04-26 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US9353081B2 (en) 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
CA2858685A1 (en) 2011-12-12 2013-06-20 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
ES2663609T3 (es) 2012-03-29 2018-04-16 Bayer Intellectual Property Gmbh Imidazopiridazinas amino-sustituidas
EP2834245B1 (en) 2012-04-04 2017-12-13 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
EP2920176B1 (en) 2012-11-19 2017-09-13 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines as mknk1 kinase inhibitors
CN105008363A (zh) 2013-01-30 2015-10-28 拜耳医药股份公司 作为mknk-1激酶抑制剂的酰氨基咪唑并哒嗪
HK1212699A1 (zh) 2013-02-20 2016-06-17 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物
CN105899512A (zh) 2014-01-09 2016-08-24 拜耳医药股份公司 可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪

Also Published As

Publication number Publication date
US20140296231A1 (en) 2014-10-02
ZA201402498B (en) 2017-09-27
AU2012306422A1 (en) 2014-03-27
ECSP14013231A (es) 2014-04-30
IL231351A (en) 2017-01-31
MY168413A (en) 2018-11-09
SI2758401T1 (sl) 2017-10-30
CA2847514A1 (en) 2013-03-14
CO6900146A2 (es) 2014-03-20
JP6174583B2 (ja) 2017-08-02
IL231351A0 (en) 2014-04-30
ES2638319T3 (es) 2017-10-19
CY1119433T1 (el) 2018-03-07
SG11201400219PA (en) 2014-03-28
ME02951B (me) 2018-07-20
AP3853A (OSRAM) 2016-09-30
AP2014007496A0 (en) 2014-03-31
MX2014002697A (es) 2014-04-25
RS56179B1 (sr) 2017-11-30
US9499547B2 (en) 2016-11-22
CN103958515A (zh) 2014-07-30
UA117092C2 (uk) 2018-06-25
EP2758401B1 (en) 2017-05-31
EA025688B1 (ru) 2017-01-30
MX348064B (es) 2017-05-26
DOP2014000051A (es) 2014-06-01
PE20141593A1 (es) 2014-11-12
WO2013034570A1 (en) 2013-03-14
DK2758401T3 (en) 2017-09-11
CN103958515B (zh) 2016-11-09
LT2758401T (lt) 2017-08-25
CL2014000543A1 (es) 2014-09-26
MA35422B1 (fr) 2014-09-01
PH12014500501A1 (en) 2021-06-02
PT2758401T (pt) 2017-08-30
JP2014525469A (ja) 2014-09-29
CR20140113A (es) 2014-05-02
PL2758401T3 (pl) 2017-11-30
GT201400043A (es) 2015-04-06
AU2012306422B2 (en) 2017-10-26
EA201400311A1 (ru) 2014-09-30
EP2758401A1 (en) 2014-07-30
HK1199732A1 (en) 2015-07-17
NZ622129A (en) 2016-06-24
BR112014004687A2 (pt) 2017-03-28
KR20140059268A (ko) 2014-05-15

Similar Documents

Publication Publication Date Title
HRP20171248T1 (hr) Amino-supstituirani imidazopiridazini
KR102566924B1 (ko) 케모카인 수용체 조절제 및 이의 용도
JP2014513704A5 (OSRAM)
TWI690525B (zh) 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
AU2018350980B2 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
JP6487925B2 (ja) セリン／トレオニンキナーゼ阻害剤
JP2017511360A5 (OSRAM)
JP2015537017A5 (OSRAM)
RS58679B1 (sr) Triazolopirimidin jednijenja i njihova upotreba
RU2018104092A (ru) Бициклические лактамы и способы их применения
KR20200125932A (ko) 케모카인 수용체 조정제 및 그의 용도
EP3472166A1 (en) Imidazopyrimidine compounds useful for the treatment of cancer
TW201808888A (zh) 整合應激途徑之調節劑
JP2016523974A5 (OSRAM)
JP2016520118A5 (OSRAM)
US20130281396A1 (en) Treatment of diseases by epigenetic regulation
JP2017538677A5 (OSRAM)
RU2018102372A (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
HRP20150517T1 (hr) Triazolopiridini
US20170015669A1 (en) Heteroarylamide inhibitors of tbk1
JP2021500340A5 (OSRAM)
US12006320B2 (en) Heterocyclic derivatives as PI3K inhibitors
CN109790158A (zh) 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
JP2016508135A5 (OSRAM)
US20220340544A1 (en) Substituted heterocyclic derivatives as pi3k inhibitors